We have determined that certain proteins, including polypeptides with Mr's of 30,000, 35,000, 24,000, and 20,000, are expressed in low- passage, virulent strains of Borrelia burgdorferi (Bb) but are absent or underexpressed in high-passage, avirulent strains. The central hypothesis of this proposal is that these 'virulence-associated proteins' are important virulence determinants and immune targets in Bb and thus will be useful in the diagnosis, epidemiology, and possible prevention of Lyme disease.
In Specific Aim 1, we will identify virulence-associated proteins of Bb by comparing the protein profiles of virulent and avirulent isogeneic variants using non-equilibrium pH gradient two dimensional gel electrophoresis (2DGE), which separates the polypeptides of Bb into a series of distinct, easily differentiated spots. The protein profiles of low-passage North American, European, and Asian strains will also be compared to determine the degree of variation and the correlation, if any, between expression of certain proteins and pathogenic properties such as a propensity for arthritogenesis.
Specific Aim 2 will consist of the biochemical and genetic characterization of selected virulence-associated proteins, and will include determination of partial amino acid sequence, gene sequence, gene location (i.e.plasmid-encoder vs. chromosomal) and structural properties. In preliminary studies, we have cloned the gene of a major, 30K, non-OspA, virulence-associated protein of the B31 strain of Bb. Analogous genes in Bb strains from different geographical locations will be examined to determine the degree of heterogeneity among Bb isolates.
In Specific Aim 3, the immune response of Lyme disease patients and Bb-infected C3H/HeN mice to the 30 kDa protein and other virulence-associated proteins will be examined to determine their utility for immunodiagnosis and immunoprotection. Antibody responses to these proteins will be determined using 2DGE Western blot reactivity and (as recombinant antigens become available) ELISA assays, testing both IgM and IgG reactivity. The possible immunoprotective activity of the virulence-associated proteins will be examined by active immunization of C3H/HeN mice with the 30K protein or other proteins and by passive protection studies with monoclonal or monospecific antibodies. This project is likely to provide exciting new information regarding these previously uncharacterized and potentially important Bb proteins, their role in pathogenesis, and their utility in Lyme disease diagnosis and prevention.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR041507-02
Application #
3161966
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1991-09-30
Project End
1994-08-31
Budget Start
1992-09-01
Budget End
1993-08-31
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Brown, E L; Ullrich, S E; Pride, M et al. (2001) The effect of UV irradiation on infection of mice with Borrelia burgdorferi. Photochem Photobiol 73:537-44
Guo, B P; Norris, S J; Rosenberg, L C et al. (1995) Adherence of Borrelia burgdorferi to the proteoglycan decorin. Infect Immun 63:3467-72
Norris, S J; Howell, J K; Garza, S A et al. (1995) High- and low-infectivity phenotypes of clonal populations of in vitro-cultured Borrelia burgdorferi. Infect Immun 63:2206-12
Carter, C J; Bergstrom, S; Norris, S J et al. (1994) A family of surface-exposed proteins of 20 kilodaltons in the genus Borrelia. Infect Immun 62:2792-9
Barbour, A G (1993) Linear DNA of Borrelia species and antigenic variation. Trends Microbiol 1:236-9
Norris, S J; Carter, C J; Howell, J K et al. (1992) Low-passage-associated proteins of Borrelia burgdorferi B31: characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein. Infect Immun 60:4662-72